Maitreya Medicare Board of Directors

Get the latest insights into the leadership at Maitreya Medicare. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Dr. Narendra Singh Tanwar Chairman & Managing Director
Dr. Pranav Rohitbhai Thaker Whole Time Director
Mrs. Abha Surana Ind. Non-Executive Director
Mr. Hardik Vikrambhai Patel Ind. Non-Executive Director
Mr. Vimalkumar Natverlal Patel Whole Time Director

Maitreya Medicare Share price

MAITREYA

245

12.00 (-4.67%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:44 IST
BUYSELL
Today's High

257.00

Today's Low

241.20

52 Week Low

214.45

52 Week High

400.00

The current prices are delayed, login to your account for live prices

Maitreya Medicare FAQs

The board at Maitreya Medicare consists of experienced professionals, including Dr. Narendra Singh Tanwar , Dr. Pranav Rohitbhai Thaker , and others, overseeing the company’s strategic and corporate governance.

Directors at Maitreya Medicare are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Dr. Narendra Singh Tanwar is the current chairman at Maitreya Medicare.

Executive directors at Maitreya Medicare are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Maitreya Medicare adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Maitreya Medicare, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.